The RIVAWAR Trial and ACS Guidelines for LV Thrombus
Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.
Listen
AAN 2025: Pharmacists Play Critical Role in Monitoring, Managing Lecanemab Therapy
April 20th 2025Philip Kuball, MD, neurology resident at NYU Langone Health, highlights the integral role of pharmacists in monitoring patient eligibility, managing dosing schedules, and ensuring safe medication interactions for lecanemab treatment in Alzheimer disease.
Watch
PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Nondiabetics
April 19th 2025These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.
Read More
The 2025 SPPCP Virtual Conference on Tuesday, May 20, 2025, will offer pharmacists and clinicians a full day of CE-accredited sessions on complex pain management, opioid use disorder, mentorship, and innovative approaches in palliative care, with opportunities for networking and professional development.
Read More
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
Published: April 18th 2025 | Updated: April 18th 2025Multiple phase 3 clinical trials demonstrated dupilumab’s (Dupixent; Regeneron, Sanofi) effectiveness in reducing hives and itch in patients with chronic spontaneous urticaria compared with placebo.
Read More